Canada Markets closed

Ceapro Inc. (CZO.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.5500-0.0100 (-1.79%)
At close: 09:30AM EST
Full screen
Previous Close0.5600
Open0.5500
Bid0.5500 x 0
Ask0.5900 x 0
Day's Range0.5500 - 0.5500
52 Week Range0.5000 - 0.9200
Volume3,500
Avg. Volume25,755
Market Cap42.72M
Beta (5Y Monthly)1.50
PE Ratio (TTM)42.31
EPS (TTM)0.0130
Earnings DateApr. 22, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Ceapro Inc. Announces R&D Funding to Support PGX Technology Project

    – PGX Technology further recognized as a disruptive technology – Additional support paves the way for the manufacturing of pharmaceutical-grade yeast beta glucan (YBG) EDMONTON, Alberta, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced they are receiving advisory services and up to

  • GlobeNewswire

    Ceapro Inc. Reports 2021 Third Quarter and Nine-Month Financial Results and Operational Highlights

    – Increased R&D activities focused on the completion of a clinical trial for oat beta glucan as a potential cholesterol reducer and on the development of yeast beta glucan as a potential inhalable therapeutic for COVID-19 – – Q3 2021 record sales of $4,523,000 compared to $3,476,000 for Q3 2020, representing a 30% increase – – Net profit of $875,000 for Q3 2021 vs. net profit of $192,000 for Q3 2020, a 356% increase – – Achieved record production levels despite COVID-19 pandemic situation – EDMO

  • GlobeNewswire

    Ceapro Inc. Reports Preliminary Results from Clinical Trial Evaluating Oat Beta Glucan in Patients with High Cholesterol Levels

    EDMONTON, Alberta, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today reported preliminary results from the clinical study entitled “A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Compare the Efficacy and Safety of High-Medium Molecular Weight Beta-Glucan a